Assessing Depression in Schizophrenia, Br J Psychiatry, vol.22, pp.39-44, 1993. ,
Enzymatic Pathways That Regulate Endocannabinoid Signaling in the Nervous System, Chemical reviews, 2008. ,
Memory impairment in schizophrenia: a meta-analysis, Am J Psychiatry, vol.156, pp.1358-1366, 1999. ,
Neurocognitive function in clinically stable men with bipolar I disorder or schizophrenia and normal control subjects, Biological Psychiatry, vol.56, issue.8, pp.560-569, 2004. ,
DOI : 10.1016/j.biopsych.2004.08.002
The Scale for the Assessment of Negative Symptoms (SANS), Br J Psychiatry, vol.7, pp.49-58, 1989. ,
Correlational Studies of the Scale for the Assessment of Negative Symptoms and the Scale for the Assessment of Positive Symptoms: An Overview and Update, Psychopathology, vol.28, issue.1, pp.7-17, 1995. ,
DOI : 10.1159/000284894
CANNABIS AND SCHIZOPHRENIA A Longitudinal Study of Swedish Conscripts, The Lancet, vol.330, issue.8574, pp.1483-1489, 1987. ,
DOI : 10.1016/S0140-6736(87)92620-1
Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study, BMJ, vol.325, issue.7374, pp.1212-1213, 2002. ,
DOI : 10.1136/bmj.325.7374.1212
Working memory): Recent advancs in learning and motivation, pp.47-90, 1974. ,
La mémoire humaine: théorie et pratique, 1993. ,
Hopkins Verbal Learning Test ? Revised: Normative Data and Analysis of Inter-Form and Test-Retest Reliability, The Clinical Neuropsychologist (Neuropsychology, Development and Cognition: Section D), vol.12, issue.1, pp.43-55, 1998. ,
DOI : 10.1076/clin.12.1.43.1726
Feasibility of central cannabinoid CB1 receptor imaging with [124I]AM281 PET demonstrated in a schizophrenic patient, Psychiatry Research: Neuroimaging, vol.147, issue.2-3, pp.249-56, 2006. ,
DOI : 10.1016/j.pscychresns.2006.02.002
Serotonin Evokes Endocannabinoid Release and Retrogradely Suppresses Excitatory Synapses, Journal of Neuroscience, vol.28, issue.25, pp.6508-6523, 2008. ,
DOI : 10.1523/JNEUROSCI.0678-08.2008
Opposite Effects of ??-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology, Neuropsychopharmacology, vol.20, issue.3, pp.764-74, 2010. ,
DOI : 10.1038/npp.2009.184
Dysregulated peripheral endocannabinoid system signaling is associated with cognitive deficits in first-episode psychosis, Journal of Psychiatric Research, vol.75, pp.14-21, 2016. ,
DOI : 10.1016/j.jpsychires.2016.01.002
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide, British Journal of Pharmacology, vol.400, issue.4, pp.845-52, 2001. ,
DOI : 10.1038/sj.bjp.0704327
Cannabinoid Modulations of Resting State EEG Theta Power and Working Memory Are Correlated in Humans, Journal of Cognitive Neuroscience, vol.21, issue.9, pp.1906-1922, 2010. ,
DOI : 10.1126/science.1060496
Rimonabant for neurocognition in schizophrenia: A 16-week double blind randomized placebo controlled trial, Schizophrenia Research, vol.134, issue.2-3, pp.207-217, 2012. ,
DOI : 10.1016/j.schres.2011.11.009
Meta-analysis of Cognitive Deficits in Ultra-high Risk to Psychosis and First-Episode Psychosis: Do the Cognitive Deficits Progress Over, or After, the Onset of Psychosis?, Schizophrenia Bulletin, vol.40, issue.4, pp.744-55, 2014. ,
DOI : 10.1093/schbul/sbt085
Acute and Non-acute Effects of Cannabis on Human Memory Function: A Critical Review of Neuroimaging Studies, Current Pharmaceutical Design, vol.20, issue.13, pp.2114-2139, 2014. ,
DOI : 10.2174/13816128113199990436
Role of the endocannabinoid system in brain functions relevant for schizophrenia: An overview of human challenge studies with cannabis or ???9-tetrahydrocannabinol (THC), Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol.52, pp.53-69, 2014. ,
DOI : 10.1016/j.pnpbp.2013.11.017
Default Mode Network in the Effects of ??9-Tetrahydrocannabinol (THC) on Human Executive Function, PLoS ONE, vol.25, issue.7, p.70074, 2013. ,
DOI : 10.1371/journal.pone.0070074.s004
Verbal Working Memory in Individuals with Schizophrenia and Their First Degree Relatives, Actas Esp Psiquiatr, vol.41, pp.106-120, 2013. ,
The role of cannabinoid 1 receptor expressing interneurons in behavior, Neurobiology of Disease, vol.63, pp.210-231, 2014. ,
DOI : 10.1016/j.nbd.2013.11.001
Brief presynaptic bursts evoke synapse-specific retrograde inhibition mediated by endogenous cannabinoids, Nature Neuroscience, vol.6, issue.10, pp.1048-57, 2003. ,
DOI : 10.1038/nn1126
Quantitative neural indicators of liability to schizophrenia: Implications for molecular genetic studies, American Journal of Medical Genetics, vol.157, issue.1, pp.16-25, 2001. ,
DOI : 10.1002/1096-8628(20010108)105:1<16::AID-AJMG1046>3.0.CO;2-Z
: A Molecular Gateway to the Pain Pathway, Annual Review of Neuroscience, vol.24, issue.1, pp.487-517, 2001. ,
DOI : 10.1146/annurev.neuro.24.1.487
Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia, NeuroImage, vol.79, pp.129-159, 2014. ,
DOI : 10.1016/j.neuroimage.2013.04.052
The Endocannabinoid System in Peripheral Lymphocytes as a Mirror of Neuroinflammatory Diseases, Current Pharmaceutical Design, vol.14, issue.23, pp.2370-2412, 2008. ,
DOI : 10.2174/138161208785740018
Specific executive dysfunction in patients with first-episode medication-na??ve schizophrenia, Schizophrenia Research, vol.82, issue.1, pp.51-64, 2006. ,
DOI : 10.1016/j.schres.2005.09.020
Le coût de la schizophrénie, 2009. ,
Cannabinoid receptor 1 gene (CNR1) and susceptibility to a quantitative phenotype for hebephrenic schizophrenia, American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, vol.21, issue.3, pp.279-84, 2008. ,
DOI : 10.1002/ajmg.b.30592
TRPV1 activation by endogenous anandamide triggers postsynaptic long-term depression in dentate gyrus, Nature Neuroscience, vol.22, issue.12, pp.1511-1519, 2010. ,
DOI : 10.1523/JNEUROSCI.4433-07.2007
Long-Term Plasticity of Endocannabinoid Signaling Induced by Developmental Febrile Seizures, Neuron, vol.39, issue.4, pp.599-611, 2003. ,
DOI : 10.1016/S0896-6273(03)00499-9
Sustained attention deficits as markers of genetic susceptibility to schizophrenia, American Journal of Medical Genetics, vol.38, issue.1, pp.52-59, 2000. ,
DOI : 10.1002/(SICI)1096-8628(200021)97:1<52::AID-AJMG7>3.0.CO;2-6
Cannabis, Cannabinoids and Schizophrenia: Integration of the Evidence, Australian & New Zealand Journal of Psychiatry, vol.28, issue.5, pp.357-68, 2008. ,
DOI : 10.1016/S0140-6736(07)61162-3
Preserved learning and retention of pattern-analyzing skill in amnesia: dissociation of knowing how and knowing that, Science, vol.210, issue.4466, pp.207-217, 1980. ,
DOI : 10.1126/science.7414331
Impaired Attention, Genetics, and the Pathophysiology of Schizophrenia, Schizophrenia Bulletin, vol.20, issue.1, pp.31-46, 1994. ,
DOI : 10.1093/schbul/20.1.31
Investigation of endocannabinoid system genes suggests association between peroxisome proliferator activator receptor-?? gene (PPARA) and schizophrenia, European Neuropsychopharmacology, vol.23, issue.7, pp.749-759, 2013. ,
DOI : 10.1016/j.euroneuro.2012.07.007
Paranoid Schizophrenia is Characterized by Increased CB1 Receptor Binding in the Dorsolateral Prefrontal Cortex, Neuropsychopharmacology, vol.56, issue.8, pp.1620-1630, 2011. ,
DOI : 10.1590/S0100-879X2006000400001
Conscious recollection in autobiographical memory: An investigation in schizophrenia, Consciousness and Cognition, vol.14, issue.3, pp.535-547, 2005. ,
DOI : 10.1016/j.concog.2005.01.005
URL : https://hal.archives-ouvertes.fr/hal-00314809
Functional Mechanisms of Episodic Memory Impairment in Schizophrenia, The Canadian Journal of Psychiatry, vol.13, issue.2, pp.693-701, 2007. ,
DOI : 10.1177/070674370705201103
Intact Implicit Learning in Schizophrenia, American Journal of Psychiatry, vol.158, issue.6, pp.944-952, 2001. ,
DOI : 10.1176/appi.ajp.158.6.944
Functional Mechanisms Underlying Impaired Recognition Memory and Conscious Awareness in Patients With Schizophrenia, Archives of General Psychiatry, vol.56, issue.7, pp.639-683, 1999. ,
DOI : 10.1001/archpsyc.56.7.639
Endocannabinoid Signalling in the Blood of Patients with Schizophrenia, Lipids Health Dis, vol.19, pp.2-5, 2003. ,
extracts on TRP channels and endocannabinoid metabolic enzymes, British Journal of Pharmacology, vol.333, issue.7, pp.1479-94, 2011. ,
DOI : 10.1111/j.1476-5381.2010.01166.x
Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use, Neuroscience, vol.103, issue.1, pp.9-15, 2001. ,
DOI : 10.1016/S0306-4522(00)00552-2
Confirmation that the AKT1 (rs2494732) Genotype Influences the Risk of Psychosis in Cannabis Users, Biological Psychiatry, vol.72, issue.10, pp.811-817, 2012. ,
DOI : 10.1016/j.biopsych.2012.06.020
High-potency cannabis and the risk of psychosis, The British Journal of Psychiatry, vol.195, issue.6, pp.488-91, 2009. ,
DOI : 10.1192/bjp.bp.109.064220
Daily Use, Especially of High-Potency Cannabis, Drives the Earlier Onset of Psychosis in Cannabis Users, Schizophrenia Bulletin, vol.40, issue.6, pp.1509-1526, 2014. ,
DOI : 10.1093/schbul/sbt181
Anandamide receptors, Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA), vol.66, issue.2-3, pp.377-91, 2002. ,
DOI : 10.1054/plef.2001.0349
FAAH and anandamide: is 2-AG really the odd one out?, Trends in Pharmacological Sciences, vol.29, issue.5, pp.229-262, 2008. ,
DOI : 10.1016/j.tips.2008.03.001
The Implication of CNR1 Gene's Polymorphisms in the Modulation of Endocannabinoid System Effects, Rom J Intern Med, vol.47, pp.9-18, 2009. ,
Is semantic memory impaired in schizophrenia? A systematic review and meta-analysis of 91 studies, Cognitive Neuropsychiatry, vol.23, issue.6, pp.473-509, 2009. ,
DOI : 10.1016/j.psychres.2003.07.009
Relative Risk of Attention Deficits in Siblings of Patients With Schizophrenia, American Journal of Psychiatry, vol.157, issue.8, pp.1309-1325, 2000. ,
DOI : 10.1176/appi.ajp.157.8.1309
Reduced Cortical Cannabinoid 1 Receptor Messenger RNA and Protein Expression in Schizophrenia, Archives of General Psychiatry, vol.65, issue.7, pp.772-84, 2008. ,
DOI : 10.1001/archpsyc.65.7.772
Cortical Glutamic Acid Decarboxylase 67 Deficiency Results in Lower Cannabinoid 1 Receptor Messenger RNA Expression: Implications for Schizophrenia, Biological Psychiatry, vol.71, issue.2, pp.114-123, 2012. ,
DOI : 10.1016/j.biopsych.2011.09.014
Abstract, Twin Research and Human Genetics, vol.32, issue.06, pp.805-816, 2007. ,
DOI : 10.1074/jbc.M504942200
An investigation of the integrity of semantic boundaries in schizophrenia, Schizophrenia Research, vol.53, issue.3, pp.187-98, 2002. ,
DOI : 10.1016/S0920-9964(01)00202-X
Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment, Journal of Psychopharmacology, vol.32, issue.1, pp.19-27, 2013. ,
DOI : 10.1007/BF00432554
Vers un modèle unifié de la mémoire, Cerveau&psycho, vol.28, pp.1-9, 2008. ,
Types and characteristics of remote memory impairment in schizophrenia, Schizophrenia Research, vol.30, issue.2, pp.155-63, 1998. ,
DOI : 10.1016/S0920-9964(97)00129-1
Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias, European Journal of Neuroscience, vol.4, issue.6, pp.1607-1621, 2003. ,
DOI : 10.1016/S0304-3940(99)00762-4
Cognitive performance and peripheral endocannabinoid system receptor expression in schizophrenia, Schizophrenia Research, vol.156, issue.2-3, pp.254-60, 2014. ,
DOI : 10.1016/j.schres.2014.04.028
Antagonistes Des Récepteurs CB1 Des Endocannabinoïdes : Quels Arguments Pour Des Effets Favorables Indépendants de La Seule Réduction Pondérale ?, Métabolismes Hormones Diabètes et Nutrition, pp.109-115, 2008. ,
Cognitive deficits in schizophrenia: an updated metanalysis of the scientific evidence, BMC Psychiatry, vol.64, issue.Suppl 2, p.64, 2012. ,
DOI : 10.1037/0022-006X.64.5.973
A Meta-Analysis of Cognitive Deficits in Adults with a Diagnosis of Schizophrenia, Neuropsychology Review, vol.108, issue.1, pp.73-95, 2005. ,
DOI : 10.1007/s11065-005-6254-9
Working memory in schizophrenia: a meta-analysis, Psychological Medicine, vol.22, issue.06, pp.889-905, 2009. ,
DOI : 10.1097/00005053-200210000-00004
A Measure of State Persecutory Ideation for Experimental Studies, The Journal of Nervous and Mental Disease, vol.195, issue.9, pp.781-785, 2007. ,
DOI : 10.1097/NMD.0b013e318145a0a9
The Cognitive Neuropsychology of Schizophrenia, Essays in Cognitive Neuropsychology, 2008. ,
Postsynaptic endocannabinoid release is critical to long-term depression in the striatum, Nature Neuroscience, vol.5, pp.446-51, 2002. ,
DOI : 10.1038/nn832
Cerebrospinal Anandamide Levels are Elevated in Acute Schizophrenia and are Inversely Correlated with Psychotic Symptoms, Neuropsychopharmacology, vol.29, issue.11, pp.2108-2122, 2004. ,
DOI : 10.1038/sj.npp.1300558
Dopamine Activation of Endogenous Cannabinoid Signaling in Dorsal Striatum, Nat Neurosci, vol.2, pp.358-63, 1999. ,
Lymphocytes as a neural probe: potential for studying psychiatric disorders, Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol.28, issue.3, pp.559-76, 2004. ,
DOI : 10.1016/j.pnpbp.2004.01.009
Forms of memory failure in schizophrenia., Journal of Abnormal Psychology, vol.101, issue.3, pp.487-94, 1992. ,
DOI : 10.1037/0021-843X.101.3.487
Working Memory Dysfunction in Schizophrenia, J Neuropsychiatry Clin Neurosci, vol.6, pp.348-57, 1994. ,
Nonverbal working memory deficits in schizophrenia patients: Evidence of a supramodal executive processing deficit, Schizophrenia Research, vol.68, issue.2-3, pp.189-201, 2004. ,
DOI : 10.1016/j.schres.2003.07.007
Postsynaptic TRPV1 triggers cell type???specific long-term depression in the nucleus accumbens, Nature Neuroscience, vol.21, issue.12, pp.1519-1544, 2010. ,
DOI : 10.1523/JNEUROSCI.0170-06.2006
Clinical Global Impression (CGI) ECDEU Assessment Manual for Psychopharmacology, 1976. ,
The Wake-Promoting Peptide Orexin-B Inhibits Glutamatergic Transmission to Dorsal Raphe Nucleus Serotonin Neurons through Retrograde Endocannabinoid Signaling, Journal of Neuroscience, vol.25, issue.4, pp.896-905, 2005. ,
DOI : 10.1523/JNEUROSCI.3258-04.2005
Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD), Revista Brasileira de Psiquiatria, vol.32, issue.1, pp.56-61, 2010. ,
DOI : 10.1590/S1516-44462010000100011
Stability of Cognitive Performance in Older Patients With Schizophrenia: An 8-Week Test-Retest Study, American Journal of Psychiatry, vol.162, issue.1, pp.110-117, 2005. ,
DOI : 10.1176/appi.ajp.162.1.110
Ca2+-assisted receptor-driven endocannabinoid release: mechanisms that associate presynaptic and postsynaptic activities, Current Opinion in Neurobiology, vol.17, issue.3, pp.360-365, 2007. ,
DOI : 10.1016/j.conb.2007.03.012
Stability and Course of Neuropsychological Deficits in Schizophrenia, Archives of General Psychiatry, vol.58, issue.1, pp.24-32, 2001. ,
DOI : 10.1001/archpsyc.58.1.24
Endocannabinoid Signaling and Long-Term Synaptic Plasticity, Annual Review of Physiology, vol.71, issue.1, pp.283-306, 2009. ,
DOI : 10.1146/annurev.physiol.010908.163149
Neurocognitive deficit in schizophrenia: A quantitative review of the evidence., Neuropsychology, vol.12, issue.3, pp.426-471, 1998. ,
DOI : 10.1037/0894-4105.12.3.426
Cannabinoid receptor localization in brain., Proceedings of the National Academy of Sciences, vol.87, issue.5, pp.19-32, 1992. ,
DOI : 10.1073/pnas.87.5.1932
Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence, Neuroscience, vol.204, pp.207-236, 2012. ,
DOI : 10.1016/j.neuroscience.2011.11.020
Dendritically released transmitters cooperate via autocrine and retrograde actions to inhibit afferent excitation in rat brain, The Journal of Physiology, vol.410, issue.2, pp.611-635, 2004. ,
DOI : 10.1113/jphysiol.2004.066159
Reduced cannabinoid CB1 receptor binding in alcohol dependence measured with positron emission tomography, Molecular Psychiatry, vol.45, issue.8, pp.916-937, 2013. ,
DOI : 10.1371/journal.pone.0023690
An fMRI Study of Episodic Encoding and Recognition of Words in Patients With Schizophrenia in Remission, American Journal of Psychiatry, vol.160, issue.5, pp.911-919, 2003. ,
DOI : 10.1176/appi.ajp.160.5.911
Ten year longitudinal study of neuropsychological functioning subsequent to a first episode of schizophrenia, Schizophrenia Research, vol.78, issue.1, pp.27-34, 2005. ,
DOI : 10.1016/j.schres.2005.05.010
Executive function in first-episode schizophrenia, Psychological Medicine, vol.28, issue.2, pp.463-73, 1998. ,
DOI : 10.1017/S0033291797006041
Effects of marijuana on neurophysiological signals of working and episodic memory, Psychopharmacology, vol.38, issue.2, pp.214-236, 2004. ,
DOI : 10.1007/s00213-004-1868-9
A systematic review of the antipsychotic properties of cannabidiol in humans, Schizophrenia Research, vol.162, issue.1-3, pp.153-61, 2015. ,
DOI : 10.1016/j.schres.2015.01.033
Neurocognitive prediction of illness knowledge after psychoeducation in schizophrenia: results from the Munich COGPIP study, Psychological Medicine, vol.30, issue.03, pp.533-577, 2011. ,
DOI : 10.1093/schbul/sbl072
Course of neurocognitive deficits in the prodrome and first episode of schizophrenia., Neuropsychology, vol.24, issue.1, pp.109-129, 2010. ,
DOI : 10.1037/a0016791
Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia, Schizophrenia Research, vol.141, issue.2-3, pp.185-193, 2012. ,
DOI : 10.1016/j.schres.2012.07.021
Étude Du Système Endocannabinoïde et Ses Implications Dans La Schizophrénie ,
A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF), The British Journal of Psychiatry, vol.166, issue.5, pp.654-663, 1995. ,
DOI : 10.1192/bjp.166.5.654
Verbal fluency in schizophrenia: relationship with executive function, semantic memory and clinical alogia, Psychological Medicine, vol.4, issue.01, pp.39-49, 1996. ,
DOI : 10.1016/0028-3932(90)90137-D
Control of synaptic function by endocannabinoid-mediated retrograde signaling, Proceedings of the Japan Academy, Series B, vol.90, issue.7, pp.235-50, 2014. ,
DOI : 10.2183/pjab.90.235
Molecular Composition of the Endocannabinoid System at Glutamatergic Synapses, Journal of Neuroscience, vol.26, issue.21, pp.5628-5665, 2006. ,
DOI : 10.1523/JNEUROSCI.0309-06.2006
The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia, Schizophrenia Bulletin, vol.13, issue.2, pp.261-276, 1987. ,
DOI : 10.1093/schbul/13.2.261
A quantitative meta-analysis of population-based studies of premorbid intelligence and schizophrenia, Schizophrenia Research, vol.132, issue.2-3, pp.220-227, 2011. ,
DOI : 10.1016/j.schres.2011.06.017
Activation of Muscarinic Acetylcholine Receptors Enhances the Release of Endogenous Cannabinoids in the Hippocampus, J Neurosci, vol.22, pp.10182-91, 2002. ,
Neurocognitive performance in subjects at ultrahigh risk for schizophrenia: a comparison with first-episode schizophrenia, Comprehensive Psychiatry, vol.52, issue.1, pp.33-40, 2011. ,
DOI : 10.1016/j.comppsych.2010.04.010
Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis, The British Journal of Psychiatry, vol.194, issue.4, pp.371-373, 2009. ,
DOI : 10.1192/bjp.bp.108.053843
Substance Use Disorder and the Early Course of Illness in Schizophrenia and Affective Psychosis, Schizophrenia Bulletin, vol.23, issue.2, pp.195-201, 1997. ,
DOI : 10.1093/schbul/23.2.195
Psychotomimetic effects at initiation of cannabis use are associated with cannabinoid receptor 1 (CNR1) variants in healthy students, Molecular Psychiatry, vol.19, issue.4, pp.402-405, 2014. ,
DOI : 10.1074/jbc.M111.336750
URL : https://hal.archives-ouvertes.fr/hal-01312815
Brain regional differences in CB1 receptor adaptation and regulation of transcription, Life Sciences, vol.92, issue.8-9, pp.446-52, 2013. ,
DOI : 10.1016/j.lfs.2012.08.023
Le problème du Binding ou de l'intégration des informations dans la schizophrénie, Neuropsychologie clinique de la schizophrénie, pp.23-54, 2011. ,
Working Memory Impairments in Schizophrenia: A Meta-Analysis., Journal of Abnormal Psychology, vol.114, issue.4, pp.599-611, 2005. ,
DOI : 10.1037/0021-843X.114.4.599
Visuospatial deficits in schizophrenia: central executive and memory subsystems impairments, Schizophrenia Research, vol.68, issue.2-3, pp.217-240, 2004. ,
DOI : 10.1016/S0920-9964(03)00215-9
RGS4 Is Required for Dopaminergic Control of Striatal LTD and Susceptibility to Parkinsonian Motor Deficits, Neuron, vol.73, issue.2, pp.347-59, 2012. ,
DOI : 10.1016/j.neuron.2011.11.015
Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: Impact of cannabis use, Schizophrenia Research, vol.94, issue.1-3, pp.29-36, 2007. ,
DOI : 10.1016/j.schres.2007.04.025
Elevated endogenous cannabinoids in schizophrenia, NeuroReport, vol.10, issue.8, pp.1665-1674, 1999. ,
DOI : 10.1097/00001756-199906030-00008
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia, Translational Psychiatry, vol.152, issue.3, 2012. ,
DOI : 10.1038/tp.2012.15
Genome Scan Meta-Analysis of Schizophrenia and Bipolar Disorder, Part II: Schizophrenia, The American Journal of Human Genetics, vol.73, issue.1, pp.34-48, 2003. ,
DOI : 10.1086/376549
Cannabis Abuse and the Course of Recent-Onset Schizophrenic Disorders, Archives of General Psychiatry, vol.51, issue.4, pp.273-282, 1994. ,
DOI : 10.1001/archpsyc.1994.03950040017002
Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum, Nature Neuroscience, vol.294, issue.2, pp.152-161, 2008. ,
DOI : 10.1038/nn2042
Presynaptic Inhibition Caused by Retrograde Signal from Metabotropic Glutamate to Cannabinoid Receptors, Neuron, vol.31, issue.3, pp.463-75, 2001. ,
DOI : 10.1016/S0896-6273(01)00375-0
Synaptically Driven Endocannabinoid Release Requires Ca2+-Assisted Metabotropic Glutamate Receptor Subtype 1 to Phospholipase C ??4 Signaling Cascade in the Cerebellum, Journal of Neuroscience, vol.25, issue.29, pp.6826-6861, 2005. ,
DOI : 10.1523/JNEUROSCI.0945-05.2005
Further investigation of the Supervisory Attentional System in schizophrenia: Planning, inhibition, and rule abstraction, Cognitive Neuropsychiatry, vol.10, issue.3, pp.175-192, 2001. ,
DOI : 10.1192/bjp.172.2.142
The endogenous cannabinoid system controls extinction of aversive memories, Nature, vol.19, issue.6897, pp.530-534, 2002. ,
DOI : 10.1016/S0306-4522(01)00336-0
(AAT)n repeat in the cannabinoid receptor gene, CNR1: association with schizophrenia in a Spanish population, AAT)n Repeat in the Cannabinoid Receptor Gene, CNR1, pp.437-478, 2006. ,
DOI : 10.1007/s00406-006-0665-3
Amnesic syndrome in schizophrenia, Psychological Medicine, vol.18, issue.04, pp.967-72, 1990. ,
DOI : 10.1192/bjp.136.4.384
Symptom assessment in schizophrenic prodromal states From Revolution to Evolution, Psychiatr Q. Moghaddam B, Javitt D Neuropsychopharmacology, vol.70, issue.37, pp.273-87, 1999. ,
Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis, The British Journal of Psychiatry, vol.192, issue.4, pp.306-313, 2008. ,
DOI : 10.1192/bjp.bp.107.046649
Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being, Psychological Medicine, vol.10, issue.02, pp.391-400, 2012. ,
DOI : 10.1192/bjp.bp.109.064220
Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study, The British Journal of Psychiatry, vol.197, issue.4, pp.285-90, 2010. ,
DOI : 10.1192/bjp.bp.110.077503
Subjective cognitive dysfunction in first-episode and chronic schizophrenic patients, Comprehensive Psychiatry, vol.42, issue.3, pp.213-219, 2001. ,
DOI : 10.1053/comp.2001.23144
Problem solving in schizophrenia: a specific deficit in planning ability, Schizophrenia Research, vol.14, issue.3, pp.235-281, 1995. ,
DOI : 10.1016/0920-9964(94)00044-9
Quantification of endocannabinoids in postmortem brain of schizophrenic subjects, Schizophrenia Research, vol.148, issue.1-3, pp.145-50, 2013. ,
DOI : 10.1016/j.schres.2013.06.013
Memory impairment in schizophrenia: Its' relationship to executive function, Schizophrenia Research, vol.21, issue.2, pp.85-96, 1996. ,
DOI : 10.1016/0920-9964(96)00038-2
Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia, Experimental Brain Research, vol.96, issue.2???3, pp.556-60, 2006. ,
DOI : 10.1007/s00221-006-0503-x
Relationship between symptom dimensions and neurocognitive functioning in schizophrenia: a meta-analysis of WCST and CPT studies, Journal of Psychiatric Research, vol.35, issue.2, pp.119-144, 2001. ,
DOI : 10.1016/S0022-3956(01)00014-0
Attention to Action, Consciousness and Self- Regulation: Advances in Research and Theory IV, 1986. ,
DOI : 10.1007/978-1-4757-0629-1_1
Endocannabinoid signalling triggered by NMDA receptor-mediated calcium entry into rat hippocampal neurons, The Journal of Physiology, vol.26, issue.2, pp.407-425, 2007. ,
DOI : 10.1113/jphysiol.2007.137505
Endocannabinoid-mediated retrograde modulation of synaptic transmission, Current Opinion in Neurobiology, vol.29, pp.1-8, 2014. ,
DOI : 10.1016/j.conb.2014.03.017
Association Study of Two Cannabinoid Receptor Genes, CNR1 and CNR2, with Methamphetamine Dependence, Current Neuropharmacology, vol.9, issue.1, pp.183-192, 2011. ,
DOI : 10.2174/157015911795017191
Biosynthetic Pathways of the Endocannabinoid Anandamide, Chemistry & Biodiversity, vol.103, issue.8, pp.1842-57, 2007. ,
DOI : 10.1002/cbdv.200790155
MAPK14 and CNR1 gene variant interactions: effects on brain volume deficits in schizophrenia patients with marijuana misuse, Psychological Medicine, vol.5, issue.03, pp.619-650, 2013. ,
DOI : 10.1001/jama.1994.03520220057031
THE BRIEF PSYCHIATRIC RATING SCALE, Psychological Reports, vol.15, issue.3, pp.799-812, 1962. ,
DOI : 10.2466/pr0.1962.10.3.799
What Do We Know About Neuropsychological Aspects Of Schizophrenia?, Neuropsychology Review, vol.86, issue.2, pp.365-84, 2009. ,
DOI : 10.1007/s11065-009-9109-y
Is it possible to be schizophrenic yet neuropsychologically normal?, Neuropsychology, vol.11, issue.3, pp.437-483, 1997. ,
DOI : 10.1037/0894-4105.11.3.437
Schizophrenics Show Spatial Working Memory Deficits, Archives of General Psychiatry, vol.49, issue.12, pp.975-82, 1992. ,
DOI : 10.1001/archpsyc.1992.01820120063009
Spatial Working Memory Deficits in the Relatives of Schizophrenic Patients, Archives of General Psychiatry, vol.52, issue.10, pp.821-829, 1995. ,
DOI : 10.1001/archpsyc.1995.03950220031007
Les cannabino??des de synth??se??: ??pid??miologie, modalit??s de consommations et effets cliniques, Toxicologie Analytique et Clinique, vol.27, issue.1, pp.33-40, 2015. ,
DOI : 10.1016/j.toxac.2014.10.002
Cognitive and clinical moderators of recognition memory in schizophrenia: a meta-analysis, Schizophrenia Research, vol.74, issue.2-3, pp.233-52, 2005. ,
DOI : 10.1016/j.schres.2004.08.017
Lifetime Prevalence of Psychotic and Bipolar I Disorders in a General Population, Archives of General Psychiatry, vol.64, issue.1, pp.19-28, 2007. ,
DOI : 10.1001/archpsyc.64.1.19
-tetrahydrocannabivarin, British Journal of Pharmacology, vol.22, issue.2, pp.199-215, 2008. ,
DOI : 10.1038/sj.bjp.0707442
Strong increase in total delta-THC in cannabis preparations sold in Dutch coffee shops, Addiction Biology, vol.249, issue.2, pp.171-80, 2005. ,
DOI : 10.1176/appi.ajp.161.3.501
A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study, International Journal of Obesity, vol.32, issue.8, pp.1243-54, 2010. ,
DOI : 10.1210/jc.85.7.2402
Bilan cognitif dans la schizophrénie: spécificités Neuropsychologie clinique de la schizophrénie, pp.101-133, 2011. ,
5. Les relations entre cognition et handicap psychique dans la schizophr??nie, Neuropsychologie clinique de la schizophrénie, pp.135-160, 2011. ,
DOI : 10.3917/dunod.prout.2011.01.0135
Polymodal activation of the endocannabinoid system in the extended amygdala, Nature Neuroscience, vol.11, issue.12, pp.1542-1549, 2011. ,
DOI : 10.2174/138161208783330790
URL : https://hal.archives-ouvertes.fr/hal-01160051
Effect of Schizophrenia on Frontotemporal Activity During Word Encoding and Recognition: A PET Cerebral Blood Flow Study, American Journal of Psychiatry, vol.158, issue.7, pp.1114-1139, 2001. ,
DOI : 10.1176/appi.ajp.158.7.1114
A default mode of brain function, Proceedings of the National Academy of Sciences, vol.98, issue.2, pp.1083-90, 2007. ,
DOI : 10.1073/pnas.98.2.676
Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia ,
Reduced levels of specific autobiographical memories in schizophrenia, Psychiatry Research, vol.117, issue.1, pp.35-45, 2003. ,
DOI : 10.1016/S0165-1781(02)00317-7
Patients with schizophrenia remember that an event has occurred, but not when, The British Journal of Psychiatry, vol.168, issue.4, pp.427-458, 1996. ,
DOI : 10.1192/bjp.168.4.427
Contribution à L'analyse et L'évaluation de Ces Concepts Dans La Schizophrénie ,
Is schizophrenia a neurodegenerative disorder?, Nordic Journal of Psychiatry, vol.8, issue.12, pp.196-201, 2009. ,
DOI : 10.1080/08039480902767286
Differential disruptions of working memory components in schizophrenia in an object???location binding task using the suppression paradigm, Journal of the International Neuropsychological Society, vol.153, issue.04, pp.510-518, 2006. ,
DOI : 10.1016/0001-6918(90)90066-O
The state of functioning of working memory in schizophrenia, Schizophrenia Research, vol.30, issue.1, pp.11-29, 1998. ,
DOI : 10.1016/S0920-9964(97)00107-2
Neuropsychological Deficit in Siblings Discordant for Schizophrenia, Schizophrenia Bulletin, vol.26, issue.4, pp.893-902, 2000. ,
DOI : 10.1093/oxfordjournals.schbul.a033503
Associations between Cannabinoid Receptor-1 (CNR1) Variation and Hippocampus and Amygdala Volumes in Heavy Cannabis Users, Neuropsychopharmacology, vol.9, issue.11, pp.2368-76, 2012. ,
DOI : 10.1038/npp.2012.92
The global cognitive impairment in schizophrenia: Consistent over decades and around the world, Schizophrenia Research, vol.150, issue.1, pp.42-50, 2013. ,
DOI : 10.1016/j.schres.2013.07.009
Cannabidiol as a potential treatment for psychosis, European Neuropsychopharmacology, vol.24, issue.1, pp.51-64, 2014. ,
DOI : 10.1016/j.euroneuro.2013.11.002
Cannabis with high cannabidiol content is associated with fewer psychotic experiences, Schizophrenia Research, vol.130, issue.1-3, pp.216-237, 2011. ,
DOI : 10.1016/j.schres.2011.04.017
Adult Version (SPI-A), Giovanni Fioriti Editore, p.97, 2007. ,
No association of CNR1 gene variations with susceptibility to schizophrenia, Neuroscience Letters, vol.426, issue.1, pp.29-33, 2007. ,
DOI : 10.1016/j.neulet.2007.08.008
Reduced binocular depth inversion in regular cannabis users, Pharmacology Biochemistry and Behavior, vol.75, issue.4, pp.789-93, 2003. ,
DOI : 10.1016/S0091-3057(03)00140-0
The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10, J Clin Psychiatry, vol.59, issue.20, pp.22-33, 1998. ,
Working Memory Deficit as a Core Neuropsychological Dysfunction in Schizophrenia, American Journal of Psychiatry, vol.160, issue.10, pp.1809-1825, 2003. ,
DOI : 10.1176/appi.ajp.160.10.1809
Effect of Chronic Administration of R-(+)-[2,3-Dihydro- 5-Methyl-3-[(morpholinyl)methyl]pyrrolo ,
212-2) or delta(9)-Tetrahydrocannabinol on Cannabinoid Receptor Adaptation in Mice, J Pharmacol Exp Ther, vol.55, issue.303, pp.36-44, 2002. ,
The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1), British Journal of Pharmacology, vol.400, issue.2, pp.227-257, 2000. ,
DOI : 10.1038/sj.bjp.0703050
Cannabis and Cognitive Dysfunction, J Psychiatry Neurosci, vol.32, pp.30-52, 2007. ,
Stahl's Essential Psychopharmacology, 2013. ,
Brain structural and clinical changes after first episode psychosis: Focus on cannabinoid receptor 1 polymorphisms, Psychiatry Research: Neuroimaging, vol.233, issue.2, pp.112-121, 2015. ,
DOI : 10.1016/j.pscychresns.2015.05.005
Synapse type-independent degradation of the endocannabinoid 2-arachidonoylglycerol after retrograde synaptic suppression, Proceedings of the National Academy of Sciences, vol.109, issue.30, pp.12195-200, 2012. ,
DOI : 10.1073/pnas.1204404109
Les Antipsychotiques : Les Médicaments Psychotropes, 2013. ,
Association study of Cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia, The Pharmacogenomics Journal, vol.107, issue.3, pp.260-266, 2012. ,
DOI : 10.1038/tpj.2010.93
Association of Single-Nucleotide Polymorphisms in the Cannabinoid Receptor 2 Gene with Schizophrenia in the Han Chinese Population, Journal of Molecular Neuroscience, vol.4, issue.1, pp.454-60, 2013. ,
DOI : 10.1007/s12031-013-0062-0
Concepts of human memory Memory: Organization and locus of change, pp.3-32, 1991. ,
Organization of memory, 1972. ,
Endocannabinoids Activate Transient Receptor Potential Vanilloid 1 Receptors to Reduce Hyperdopaminergia-Related Hyperactivity: Therapeutic Implications, Biological Psychiatry, vol.59, issue.6, pp.508-523, 2006. ,
DOI : 10.1016/j.biopsych.2005.08.019
CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia, Molecular Psychiatry, vol.7, issue.5, pp.515-523, 2002. ,
DOI : 10.1038/sj.mp.4001029
Practice and the Dynamic Nature of Working Memory, The Automatic Brain, vol.3, pp.47-79, 2009. ,
Gros Plan Sur Les Endocannabinoïdes, de Nouveaux Agents Thérapeutiques Chimie nouvelle, pp.102-105, 2004. ,
Le syst??me endocannabino??de central, m??decine/sciences, vol.20, issue.1, pp.45-53, 2004. ,
DOI : 10.1051/medsci/200420145
Rem??diation cognitive de??la??schizophr??nie. Pr??sentation du??programme RECOS, Annales M??dico-psychologiques, revue psychiatrique, vol.165, issue.3, pp.200-205, 2007. ,
DOI : 10.1016/j.amp.2007.01.008
M??moire, m??moires : l???exploration de la m??moire autobiographique dans la schizophr??nie, L'Enc??phale, vol.33, issue.3, pp.365-373, 2007. ,
DOI : 10.1016/S0013-7006(07)74582-7
Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia, The International Journal of Neuropsychopharmacology, vol.12, issue.05, pp.599-614, 2009. ,
DOI : 10.1017/S1461145708009371
Interview-based assessment of cognition in schizophrenia: Applicability of the Schizophrenia Cognition Rating Scale (SCoRS) in different phases of illness and settings of care, Schizophrenia Research, vol.146, issue.1-3, pp.217-240, 2013. ,
DOI : 10.1016/j.schres.2013.02.035
Neural Plasticity: The Biological Substrate For Neurorehabilitation, PM&R, vol.2, issue.12, pp.208-227, 2010. ,
DOI : 10.1016/j.pmrj.2010.10.016
Default Mode Network Activity and Connectivity in Psychopathology, Annual Review of Clinical Psychology, vol.8, issue.1, pp.49-76, 2012. ,
DOI : 10.1146/annurev-clinpsy-032511-143049
correction: Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses, Nature, vol.410, issue.6840, pp.588-592, 2001. ,
DOI : 10.1038/35082121
Premorbid IQ in Schizophrenia: A Meta-Analytic Review, American Journal of Psychiatry, vol.165, issue.5, pp.579-87, 2008. ,
DOI : 10.1176/appi.ajp.2008.07081242
Chlorpromazine Equivalent Doses for the Newer Atypical Antipsychotics, The Journal of Clinical Psychiatry, vol.64, issue.6, pp.663-670, 2003. ,
DOI : 10.4088/JCP.v64n0607
CA1 Pyramidal Cell Theta-Burst Firing Triggers Endocannabinoid-Mediated Long-Term Depression at Both Somatic and Dendritic Inhibitory Synapses, Journal of Neuroscience, vol.33, issue.34, pp.13743-57, 2013. ,
DOI : 10.1523/JNEUROSCI.0817-13.2013
Cannabis, COMT and psychotic experiences, The British Journal of Psychiatry, vol.199, issue.5, pp.380-385, 2011. ,
DOI : 10.1192/bjp.bp.111.091421
Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia, Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol.28, issue.2, pp.355-60, 2004. ,
DOI : 10.1016/j.pnpbp.2003.11.005
Human cannabinoid receptor 1: 5??? exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse, Molecular Psychiatry, vol.9, issue.10, pp.916-931, 2004. ,
DOI : 10.1038/sj.mp.4001560
A Critical Review of the Antipsychotic Effects of Cannabidiol: 30 Years of a Translational Investigation, Current Pharmaceutical Design, vol.18, issue.32, pp.5131-5171, 2012. ,
DOI : 10.2174/138161212802884681
Cannabidiol for the treatment of psychosis in Parkinson's disease, Journal of Psychopharmacology, vol.23, issue.8, pp.979-83, 2009. ,
DOI : 10.1177/0269881108096519
Cannabidiol monotherapy for treatment-resistant schizophrenia, Journal of Psychopharmacology, vol.16, issue.212, pp.683-689, 2006. ,
DOI : 10.1177/0269881106060967
Antipsychotic Effect of Cannabidiol, J Clin Psychiatry, vol.56, pp.485-491, 1995. ,